Florence S. Namour
Romainville, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
Journal: Clinical and translational science
Published: April 18, 2023
ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis.
Journal: Clinical pharmacology and therapeutics
Published: April 05, 2023
Filgotinib: A Clinical Pharmacology Review.
Journal: Clinical pharmacokinetics
Published: April 10, 2022
Ziritaxestat Drug-Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition.
Journal: Clinical pharmacology and therapeutics
Published: February 16, 2022
Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Journal: Clinical pharmacokinetics
Published: April 07, 2019
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 06, 2019
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: November 09, 2018
The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: May 10, 2018
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Journal: British journal of clinical pharmacology
Published: March 20, 2018
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: July 08, 2016
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.
Journal: Investigational new drugs
Published: December 04, 2015
Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Journal: Clinical pharmacokinetics
Published: October 21, 2015
Last Updated: 09/26/2026